INCY · Incyte Corporation
Is INCY setting up for a breakout, what are traders on X and the news saying, are its insiders buying, and how is the business doing? Everything Raspberry Trades measures on Incyte Corporation, in one place.
Today's breakout radarIs INCY setting up for a breakout?
Breakout Radar API →Not today. INCY is not on today's radar: no tight base just under a resistance that has been tested again and again.
See the stocks that are setting up today →What are traders on X saying about INCY?
Stock Sentiment API →Bulls: At ESMO 2026, Incyte's KRAS G12D inhibitor INCB161734 in refractory metastatic colorectal cancer with 1200 mg +/- cetuximab showed ORR 36%, DCR 100%, mPFS 7.2 months and no unexpected treatment-related adverse events, with improved KRAS G12D ctDNA suppression on the combo; in pancreatic cancer, Phase 1 data with chemo showed up to 81% response as a Phase 3 starts, and the company says the drug induces lasting tumor responses and sees itself 'neck and neck' with Revolution Medicines. The molecule is an ON/OFF inhibitor, which bulls call a key distinction in G12D where both conformations can play a role in disease maintenance, and the mutation is found in around 40% of pancreatic cancers. Analyst targets stand at $152 Buy (HC Wainwright), $130 Market Perform (BMO) and $120 Outperform (Oppenheimer), and one post argues Incyte has the balance sheet to acquire SNDX (saving ~$300M over five years on Niktimvo, with Reviforj a fit that would smooth the Jakafi-to-povo transition).
Bears: Bears argue Revolution Medicines' zoldon has similar efficacy to Incyte's drug but much better tolerability, questioning whether baseline liver metastases were comparable. Posts also flag that selective G12D inhibitors from RVMD, INCY and VSTM require high mg doses and cause scores of GI/vomiting side effects, and that daraxonrasib causes its fair share of nausea/vomit, making the ERAS November update interesting.
Reading from Oct 28, 2026; each post classified by AI, weighted by engagement.
What is the news saying about INCY?
News Sentiment API →No recent news reading for INCY. The News Sentiment API reads today's headlines on any US stock.
Are INCY insiders buying or selling?
Insider Trading API →Open-market trades only, from SEC Form 4 filings — option exercises, tax withholding and grants are left out.
- Sold · CAGNONI PABLO J$298K · Oct 15, 2026
- Sold · CAGNONI PABLO J$1.7M · Sep 15, 2026
- Sold · CAGNONI PABLO J$1.1M · Sep 15, 2026
- Sold · CAGNONI PABLO J$1.4M · Aug 19, 2026
- Sold · CAGNONI PABLO J$1.3M · Aug 12, 2026
How is Incyte Corporation's business doing?
Financial Statements API →| Quarter ended | Revenue | vs year before | Net income | EPS |
|---|---|---|---|---|
| Mar 31, 2026 | $1.3B | +21% | $303.3M | $1.47 |
| Sep 30, 2025 | $1.4B | +20% | $424.2M | $2.11 |
| Jun 30, 2025 | $1.2B | +16% | $405.0M | $2.04 |
| Mar 31, 2025 | $1.1B | +20% | $158.2M | $0.80 |
From the company's SEC filings (10-Q and 10-K).
What does Incyte Corporation expect?
Company Guidance API →- full year 2026 · total net sales · 8-K filed Jul 28, 2026
“Incyte is raising its full year 2026 total net sales guidance to $5,130 - $5,260 million”
- full year 2026 · opzelura net sales · 8-K filed Jul 28, 2026
“Incyte is raising its full year 2026 Opzelura net sales guidance to $1,050 - $1,100 million”
- full year 2026 · hematology and oncology net sales · 8-K filed Jul 28, 2026
“full year 2026 Hematology and Oncology net sales guidance to $860 - $890 million”
- full year 2026 · total gaap r&d and sg&a operating expenses · 8-K filed Jul 28, 2026
“Total GAAP R&D and SG&A operating expense guidance is $4,915 - $4,995 million”
Quoted from the outlook the company filed with the SEC.
Free account, no card: today's top 5 with charts, by email before the open.
Measured data, not recommendations. Not investment advice.